Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: 10-year follow-up of a phase 3 multicentre, observer-blind, randomised, controlled trial.

Authors:
Ouzama Henry
Ouzama Henry
Department of Pediatrics; National Taiwan University Hospital; Taipei
Taiwan
Roman Chlibek
Roman Chlibek
University of Defence
Czech Republic
Susanna Esposito
Susanna Esposito
Università degli Studi di Milano
Italy
Leif Gothefors
Leif Gothefors
Norrlands universitetssjukhus
Sorin Man
Sorin Man
"Iuliu Hatieganu" University of Medicine and Pharmacy
Romania

Lancet Infect Dis 2019 Mar 11;19(3):287-297. Epub 2019 Feb 11.

University of Defence, Faculty of Military Health Sciences, Hradec Kralove, Czech Republic; Charles University, Faculty of Medicine in Hradec Kralove, Department of Social Medicine, Hradec Kralove, Czech Republic.

Background: The duration of protection provided by varicella vaccines is unclear. We assessed the 10-year vaccine efficacy of two doses of a combined measles-mumps-rubella-varicella vaccine (MMRV), one live attenuated varicella vaccine (V) dose given after one measles-mumps-rubella vaccine (MMR) dose (MMR + V), versus two MMR doses (control vaccine) for the prevention of confirmed varicella.

Methods: This was a phase 3b follow-up of an observer-blinded, randomised, controlled trial. In phase a, children aged 12-22 months (at first vaccination) from Czech Republic (Czechia), Greece, Italy, Lithuania, Norway, Poland, Romania, Russia, Slovakia, and Sweden were randomly assigned by computer-generated randomisation list (3:3:1) to receive two doses of MMRV, one dose of MMR and one dose of varicella vaccine, or two doses of MMR, 42 days apart. Varicella cases were confirmed by detection of viral DNA, or epidemiological link and clinical assessment, by an independent data monitoring committee; disease severity was based on a modified Vázquez scale. Hazard ratios for MMRV and MMR + V versus MMR estimated in the per-protocol cohort using a Cox proportional hazards regression model were used to calculate vaccine efficacy and 95% CI. Serious adverse events were recorded throughout the study in all vaccinated children. Study objectives were secondary and descriptive. The trial is registered at ClinicalTrials.gov, number NCT00226499.

Findings: Between Sept 1, 2005, and May 10, 2006, 5803 children (mean age 14·2 months, SD 2·5) were vaccinated. The per-protocol cohort included 2279 children from the MMRV group, 2266 from the MMR + V group, and 744 from the MMR group. From baseline to a median follow-up of 9·8 years, 76 (3%) children in the MMRV group, 469 (21%) in the MMR + V group, and 352 (47%) in the MMR group had varicella. Vaccine efficacy against all varicella was 95·4% (95% CI 94·0-96·4) for MMRV and 67·2% (62·3-71·5) for MMR + V; vaccine efficacy against moderate or severe varicella was 99·1% (97·9-99·6) for MMRV and 89·5% (86·1-92·1) for MMR + V. During phase b, serious adverse events were reported by 290 (15%) of 1961 children in the MMRV group, 317 (16%) of 1978 in the MMR + V group, and 93 (15%) of 641 in the MMR group. There were no treatment-related deaths.

Interpretation: The 10-years vaccine efficacy observed, suggests that a two-dose schedule of varicella vaccine provided optimum long-term protection for the prevention of varicella by offering individual protection against all severities of disease and leading to a potential reduction in transmission, as observed in the US experience with universal mass vaccination.

Funding: GlaxoSmithKline Biologicals.

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S14733099183071
Publisher Site
http://dx.doi.org/10.1016/S1473-3099(18)30716-3DOI Listing
March 2019
14 Reads

Publication Analysis

Top Keywords

varicella vaccine
20
vaccine efficacy
20
vaccine
13
children mmrv
12
mmr + v group
12
mmr group
12
mmrv group
12
varicella
10
group
9
mmrv
8
randomised controlled
8
controlled trial
8
adverse events
8
mmr dose
8
serious adverse
8
mmr + v versus
8
versus mmr
8
mmr
8
per-protocol cohort
8
measles-mumps-rubella-varicella vaccine
8

Similar Publications